Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meclofenamate in Recurrent or Progressive Brain Metastasis
NCT02429570Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2015
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Meclofenamic acid in brain metastasis (BM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Feasibility at 2 months. Started Apr 2015; status: active, not recruiting.
02
Drugs
Meclofenamic acid
03
Conditions
brain metastasis (BM)
Beyond the preview
Go deeper on NCT02429570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429570.